MyFinsight
Home
Blog
About
Redemption of term deposits
$64,940K
Decrease in r&d benefit
receivable
-$12,924K
Proceeds from issue of
ordinary shares
$2K
Decrease in trade and
other payables
$2,204K
Share-based compensation
expense
$1,308K
Net foreign
exchange impacts
-$178K
Depreciation expense
$73K
Amortization expense
$35K
Income tax expense
$1K
Net cash provided
by/(used in) investing...
$64,940K
Net cash used in
operations
$1,518K
Net cash provided by
financing activities
$2K
Canceled cashflow
$15,205K
Increase/(decrease) in cash and cash
equivalents
$66,460K
Net loss
-$12,268K
(increase)/decrease in other current
assets
$2,329K
Other income, net
$584K
Decrease in operating
lease liabilities
-$24K
Back
Back
Cash Flow
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)
source: myfinsight.com